'''Doxefazepam''' (marketed under brand name '''Doxans''') is a [[benzodiazepine]] derivative drug developed by Schiapparelli in the 1970s.<ref>DE Patent 2338058 - BENZODIAZEPINVERBINDUNGEN FUER DIE THERAPIE</ref> It possesses [[anxiolytic]], [[anticonvulsant]], [[sedative]] and [[skeletal muscle relaxant]] properties. It is used therapeutically as a [[hypnotic]].<ref>{{cite journal |pmid=6483162 |year=1984 |last1=Rodriguez |first1=G |last2=Rosadini |last3=Sannita |last4=Strumia |title=Effects of doxefazepam on normal sleep. An EEG and neuropsychological study |volume=11 |issue=2 |pages=133–9 |journal=Neuropsychobiology |first2=G |first3=WG |first4=E |doi=10.1159/000118066}}</ref> According to Babbini and colleagues in 1975, this derivative of [[flurazepam]] was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals.<ref name=SAS_643_1975>{{cite journal | vauthors=Babbini M, Torrielli MV, Strumia E, Gaiardi M, Bartoletti M, De Marchi F  |date=August 1975 | title = Sedative-hypnotic properties of a new benzodiazepine in comparison with flurazepam. Pharmacological and clinical findings | journal = Arzneimittel-Forschung | volume = 25 | issue = 8 | pages = 1294–1300 | pmid = 241364 }}</ref> Section 5.5 of the article ''Doxefazepam'' in volume 66 of the [[World Health Organization|World Health Organization's]] (WHO) and [[International Agency for Research on Cancer|International Agency for Research on Cancer's]] (IARC) ''IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans'', an article describing the carcinogenic/toxic effects of doxefazepam on humans and experimental animals, states that there is "inadequate evidence in humans for the [[carcinogen]]icity of doxefazepam" and limited evidence in experimental for the carcinogenicity of doxefazepam," and concluded that the overall evaluation of the substance's carcinogenicity to humans is "not classifiable."<ref>{{cite journal |date=13–20 Feb 1996 |title=Doxefazepam |url=http://monographs.iarc.fr/ENG/Monographs/vol66/mono66-7.pdf |journal=IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans |publisher=International Agency For Research On Cancer (IARC) |volume=66 |pages=97–104 |accessdate=10 July 2014}}</ref>
